^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (TRANSCEND-CLL-004) (NCT03331198)
    Phase 1/2
    Juno Therapeutics, a Subsidiary of Celgene
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    11/27/2017
    Primary completion :
    11/26/2027
    Completion :
    11/26/2027
    PLCG2 • CD5
    |
    CD19 positive • PLCG2 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel)
    Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (AMC-112) (NCT05077527)
    Phase 1
    AIDS Malignancy Consortium
    Not yet recruiting
    Last update posted :
    05/14/2024
    Initiation :
    07/20/2024
    Primary completion :
    01/31/2026
    Completion :
    01/31/2027
    CD4
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • cyclophosphamide intravenous
    Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL (CYTB323A12101) (NCT03960840)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    06/26/2019
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT04240808)
    Phase 1
    University of Colorado, Denver
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    07/17/2020
    Primary completion :
    03/24/2023
    Completion :
    12/01/2024
    CD19
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (NCT03512405)
    Phase 1/2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    08/02/2019
    Primary completion :
    10/30/2024
    Completion :
    10/30/2024
    PD-L1
    |
    CD19 positive
    |
    Keytruda (pembrolizumab) • Blincyto (blinatumomab)
    Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (NCT03016377)
    Phase 1/2
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    03/22/2012
    Primary completion :
    04/22/2026
    Completion :
    04/22/2041
    ABL1 • BCR • CD19
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • iC9-CAR19 cells • rimiducid (AP1903)
    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (NCT01853631)
    Phase 1
    Baylor College of Medicine
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    02/01/2014
    Primary completion :
    12/01/2024
    Completion :
    02/01/2036
    CD19
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) (NCT02631044)
    Phase 1
    Juno Therapeutics, a Subsidiary of Celgene
    Active, not recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/06/2016
    Primary completion :
    05/10/2024
    Completion :
    05/10/2024
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement
    |
    Breyanzi (lisocabtagene maraleucel)
    Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (NCT04827745)
    Phase 2
    University of Maryland, Baltimore
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    06/11/2021
    Primary completion :
    06/30/2024
    Completion :
    08/01/2027
    CD81
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (NCT05554939)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/11/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    BCL2 • CCND1 • BCL6
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)
    Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NCT06005649)
    Phase 1/2
    Juventas Cell Therapy Ltd.
    Not yet recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/31/2024
    Primary completion :
    12/01/2024
    Completion :
    09/01/2026
    BCL2 • BCL6 • IL6 • CD22
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • HY004
    Chidamide Bridging for CAR-T Therapy (NCT05370547)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    05/25/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    BCL2 • BCL6 • PMAIP1
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT04586478)
    Phase 2
    Juventas Cell Therapy Ltd.
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    10/26/2020
    Primary completion :
    06/30/2024
    Completion :
    09/30/2025
    BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • Yuanruida (inaticabtagene autoleucel)
    CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (NCT03233854)
    Phase 1
    Crystal Mackall, MD
    Active, not recruiting
    Last update posted :
    02/28/2024
    Initiation :
    09/01/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2035
    CD19 • CD22
    |
    CD19 positive • CD19 expression • CD22 expression
    |
    cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous
    TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II (NCT05848687)
    Phase 1/2
    Tanja Andrea Gruber
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    11/03/2023
    Primary completion :
    12/01/2028
    Completion :
    12/01/2033
    KMT2A
    |
    CD19 positive
    |
    bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • ziftomenib (KO-539) • mercaptopurine
    Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL (NCT05779930)
    Phase 1
    Nationwide Children's Hospital
    Not yet recruiting
    Last update posted :
    02/09/2024
    Initiation :
    04/01/2024
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    CD19
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide
    CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (UHKT-CAR19-01) (NCT05054257)
    Phase 1
    Institute of Hematology and Blood Transfusion, ...
    Recruiting
    Last update posted :
    01/04/2024
    Initiation :
    06/02/2021
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    CD19
    |
    CD19 positive • CD19 expression
    Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (NCT05420493)
    Phase 1
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    01/04/2024
    Initiation :
    09/06/2021
    Primary completion :
    09/30/2024
    Completion :
    09/30/2025
    BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • puqilunsai (pCAR-19B)
    Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (MB106-CD20-001) (NCT05360238)
    Phase 1/2
    Mustang Bio
    Recruiting
    Last update posted :
    12/20/2023
    Initiation :
    05/24/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2026
    BCL2 • CD20 • BCL6
    |
    CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    MB-106
    Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL (NCT03919526)
    Phase 1
    Shanghai General Hospital, Shanghai Jiao Tong U...
    Completed
    Last update posted :
    12/08/2023
    Initiation :
    08/11/2019
    Primary completion :
    11/01/2023
    Completion :
    11/01/2023
    CD22
    |
    CD19 positive • CD22 positive
    |
    cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
    A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676)
    Phase 2
    Juno Therapeutics, a Subsidiary of Celgene
    Completed
    Last update posted :
    12/06/2023
    Initiation :
    11/29/2018
    Primary completion :
    09/22/2023
    Completion :
    09/22/2023
    BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Breyanzi (lisocabtagene maraleucel)
    Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant (NCT05222438)
    Phase 2
    Barbara Ann Karmanos Cancer Institute
    Withdrawn
    Last update posted :
    11/01/2023
    Initiation :
    04/08/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MYC • BCL2 • CD19 • BCL6
    |
    CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    Zynlonta (loncastuximab tesirine-lpyl)
    CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL) (NCT06101381)
    Phase 1/2
    University of Sao Paulo
    Not yet recruiting
    Last update posted :
    10/26/2023
    Initiation :
    10/01/2023
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    BCL2
    |
    CD19 positive • MYC rearrangement • CD19 expression
    QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (NCT06056752)
    Phase 1
    Anhui Provincial Hospital
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    09/27/2023
    Primary completion :
    07/03/2025
    Completion :
    07/03/2026
    IL6 • TNFA • IL2 • IL10
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (NCT06092047)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Not yet recruiting
    Last update posted :
    10/20/2023
    Initiation :
    10/01/2023
    Primary completion :
    07/01/2026
    Completion :
    04/01/2028
    IL6
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma (NCT06047197)
    Phase 1
    Beijing Yongtai Ruike Biotechnology Company Ltd
    Recruiting
    Last update posted :
    09/21/2023
    Initiation :
    09/05/2023
    Primary completion :
    09/05/2026
    Completion :
    12/05/2026
    MYC • BCL2 • BCL6
    |
    CD20 positive • CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies (NCT06037018)
    Phase 1
    CytoCares Inc
    Recruiting
    Last update posted :
    09/14/2023
    Initiation :
    08/07/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    CD8 • CD4
    |
    CD19 positive
    TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL (NCT06014073)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    09/11/2023
    Initiation :
    09/06/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • ET-901
    Safety and Efficacy Evaluation of CD19-UCART (U-CART) (NCT03229876)
    Phase N/A
    Bioray Laboratories
    Suspended
    Last update posted :
    07/24/2023
    Initiation :
    06/01/2019
    Primary completion :
    12/15/2023
    Completion :
    12/30/2023
    CD19
    |
    CD19 positive • CD19 expression
    |
    cyclophosphamide • BRL-301
    Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. (HOVON146ALL) (NCT03541083)
    Phase 2
    Stichting Hemato-Oncologie voor Volwassenen Ned...
    Active, not recruiting
    Last update posted :
    07/13/2023
    Initiation :
    06/04/2018
    Primary completion :
    11/30/2020
    Completion :
    12/15/2026
    ABL1 • BCR
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL (NCT05631912)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    07/06/2023
    Initiation :
    06/30/2023
    Primary completion :
    12/15/2024
    Completion :
    12/15/2025
    BCL2 • CCND1 • BCL6 • IL6 • TNFA • IL2 • IL10
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • autologous TRAC locus-inserted CD19-STAR-T
    Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL (NCT05252403)
    Phase 2
    Fondazione Matilde Tettamanti Menotti De Marchi...
    Recruiting
    Last update posted :
    05/04/2023
    Initiation :
    12/01/2021
    Primary completion :
    12/01/2024
    Completion :
    03/01/2025
    CD19
    |
    CD19 positive • CD19 expression
    |
    CARCIK-CD19
    CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271410)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    06/01/2019
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    CD19
    |
    CD19 positive • CD19 expression
    |
    puqilunsai (pCAR-19B)
    Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271800)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    12/01/2019
    Primary completion :
    12/31/2023
    Completion :
    07/01/2024
    CD19
    |
    CD19 positive • CD19 expression
    |
    puqilunsai (pCAR-19B)
    A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma (NCT04232826)
    Phase 1
    Juventas Cell Therapy Ltd.
    Completed
    Last update posted :
    03/28/2023
    Initiation :
    01/15/2020
    Primary completion :
    01/01/2021
    Completion :
    11/01/2022
    PD-L1 • BCL2 • BCL6
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV • Yuanruida (inaticabtagene autoleucel)
    Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (NCT03109093)
    Phase 2
    Goethe University
    Completed
    Last update posted :
    03/21/2023
    Initiation :
    03/15/2017
    Primary completion :
    08/15/2021
    Completion :
    03/10/2023
    CD19
    |
    CD19 positive • CD19 expression
    |
    Blincyto (blinatumomab)
    CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL (NCT04877080)
    Phase 1
    920th Hospital of Joint Logistics Support Force...
    Withdrawn
    Last update posted :
    02/10/2023
    Initiation :
    05/05/2021
    Primary completion :
    06/30/2023
    Completion :
    12/31/2023
    IL6 • IL2 • IL10
    |
    CD19 positive • CD19 expression • CD20 negative
    |
    AZD0120
    Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia (NCT05210907)
    Phase 1
    Seoul National University Hospital
    Recruiting
    Last update posted :
    02/06/2023
    Initiation :
    02/15/2022
    Primary completion :
    09/30/2025
    Completion :
    08/31/2026
    CD19
    |
    CD19 positive • CD19 expression
    |
    SNUH-CD19-CAR-T
    To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors (NCT05388695)
    Phase 1
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    01/13/2023
    Initiation :
    04/08/2022
    Primary completion :
    03/30/2025
    Completion :
    05/01/2025
    CD20 • CD22
    |
    CD20 positive • CD19 positive • CD22 positive • CD19 positive + CD20 positive
    To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL (NCT05651191)
    Phase 1
    Hrain Biotechnology Co., Ltd.
    Recruiting
    Last update posted :
    12/14/2022
    Initiation :
    10/21/2022
    Primary completion :
    09/30/2024
    Completion :
    09/30/2025
    IL6 • IL15
    |
    CD19 positive
    |
    anti-CD19 DASH CAR-T
    Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (NCT05563545)
    Phase 1
    Shanghai Simnova Biotechnology Co.,Ltd.
    Completed
    Last update posted :
    11/28/2022
    Initiation :
    07/21/2022
    Primary completion :
    11/25/2022
    Completion :
    11/25/2022
    CD19
    |
    CD19 positive
    |
    cyclophosphamide • SNC103